Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Shire Pharmaceuticals

Article Abstract:

Shire Pharmaceuticals has performed well since Rolf Stahel took over running the company in 1994. European Union authorities have approved the company's Alzheimer's treatment, Reminyl, which could gain a 20% stake in a market that is expanding. The company's Adderall attention deficit treatment is performing well, though Shire is still dependent on this drug for much of its profits, and does not have its own drug discovery. Shire has five proprietary drug-delivery techniques.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Shire Pharmaceuticals

Article Abstract:

Shire Pharmaceuticals has a strong growth record through acquisitions, and the company's drug development strategy is low risk. There could be pressure on prices in US markets.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Shire Pharmaceuticals: young at heart

Article Abstract:

Shire Pharmaceuticals plans a launch on the UK stock market in Feb 1996. The company is seeking to raise 20 million pounds sterling in order to develop new drugs. The company specializes in drugs for illnesses related to old age, and should benefit from the strong performance of the UK pharmaceutical industry. The company redevelops drugs which are then licensed, and also has a number of prescription drugs such as calcium supplements, a market segment where Shire accounts for 50% of the UK market.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Drugs, Shire Pharmaceuticals Group PLC
Similar abstracts:
  • Abstracts: Start spreading the news: New York is back as an incentive destination. 3 reasons housewares motivate
  • Abstracts: Guidelines clarify accounting for websites; IRS to offer tax rules. Let a CRT cut income taxes, increase estate, cash flow
  • Abstracts: Research notes and communications management and organizational change: a note on the railroad industry. Timing, order and durability of new product advantages with imitation
  • Abstracts: Learning from competing partners: outcomes and durations of scale and link alliances in Europe, North America and Asia
  • Abstracts: A matter of principles: The UK's Statement of Principles already has an impressive record and should be recognized as a force for good
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.